EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes

Takatoshi Sakata, Kazuo Kunisawa, Masaya Hasegawa iD, Yumiko Seto, Aoi Ogawa, Hitomi Kurahashi, Yasuko Yamamoto, Masao Takemura, Hidetoshi Matunami, Tomoya Sugai, Noriki Kutsumura, Kuniaki Saito und 2 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Takatoshi Sakata und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Medical …. Hauptthemen laut MEDLINE: Norepinephrine, Major Depressive Disorder, Sucrose, Antidepressive Agents. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan Science and Technology Agency (JST) FOREST Program, SPRING Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress (CUMS) and were evaluated by behavioural, neurochemical and metabolic analysis. Key Results Health check‐up data showed increased sucrose intake in MDD patients. When mice received sucrose under CUMS, hyperactivity and aggression were attenuated, although social deficits or behavioural despair induced by CUMS persisted, and recognition memory was impaired. The behavioural changes were associated with dysfunction of the locus coeruleus‐prefrontal cortex circuit, caused by impaired noradrenaline release due to presynaptic α 2 ‐adrenoceptor upregulation, and postsynaptic α 1 ‐adrenoceptor and β 1 ‐adrenoceptor downregulation. α 2 ‐Adrenoceptor antagonism by atipamezole rescued behavioural changes induced by sucrose intake under CUMS, whereas α 2 ‐adrenoceptor agonism by guanfacine in CUMS mice mimicked these behavioural changes. Among the antidepressants, mirtazapine effectively increased noradrenaline release and rescued behavioural changes induced by sucrose intake under CUMS. Sucrose intake under CUMS induced peripheral hyperglycaemia and dysregulation of central glucose metabolism. Glucose transporter inhibition by phloretin rescued behavioural changes induced by sucrose intake under CUMS. Intracerebroventricular and systemic streptozotocin administration reproduced these behavioural changes and α 2 ‐adrenoceptor upregulation. Conclusions and Implications Our findings suggest that the observed behavioural changes are associated with dysfunction of the noradrenergic α 2 ‐adrenoceptor system induced by impaired glucose metabolism. These insights targeting the noradrenergic‐metabolic axis might be a new strategy for sugar‐induced depression subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NorepinephrineMajor Depressive DisorderSucroseAntidepressive AgentsAnimalsMaleMiceHumansMice, Inbred C57BLAdultStress, PsychologicalMiddle AgedBehavior, AnimalFemale

Stichwörter der Autor:innen

adrenoceptordiabetesmajor depressive disordermousenoradrenalinesucrose

Substanzen

NorepinephrineSucroseAntidepressive Agents

Autor:innen und Institutionen

  • Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University, Graduate School of Medical Sciences, Toyoake, Japan.
  • International Center for Brain Science (ICBS), Fujita Health University, Toyoake, Japan.
  • Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan.
  • Advanced Diagnostic System Development, Fujita Health University, Graduate School of Medical Sciences, Toyoake, Japan.
  • Matsunami Research Park, Gifu, Japan.
  • Matsunami General Hospital, Gifu, Japan.

ORCID-Profile: Masaya Hasegawa, Akihiro Mouri

Förderung

  • Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science
  • Japan Science and Technology Agency (JST) FOREST Program
  • SPRING Program
  • Education and Research Facility of Animal Models for Human Diseases at Fujita Health University
  • Smoking Research Foundation
  • Takeda Science Foundation

Zitieren

APA

Sakata, T., Kunisawa, K., Hasegawa, M., Seto, Y., Ogawa, A., Kurahashi, H., Yamamoto, Y., Takemura, M., Matunami, H., Sugai, T., Kutsumura, N., Saito, K., Nabeshima, T., & Mouri, A. (2025). Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes. British Journal of Pharmacology. https://doi.org/10.1111/bph.70288

Vancouver

Sakata T, Kunisawa K, Hasegawa M, Seto Y, Ogawa A, Kurahashi H, et al. Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes. British Journal of Pharmacology. 2025. doi:10.1111/bph.70288

BibTeX
@article{Sakata2025,
  author = {Sakata, Takatoshi and Kunisawa, Kazuo and Hasegawa, Masaya and Seto, Yumiko and Ogawa, Aoi and Kurahashi, Hitomi and Yamamoto, Yasuko and Takemura, Masao and Matunami, Hidetoshi and Sugai, Tomoya and Kutsumura, Noriki and Saito, Kuniaki and Nabeshima, Toshitaka and Mouri, Akihiro},
  title = {Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70288}
}
Kostenlos starten →